Inc. (Nasdaq: NVAX ) announced today it has manufactured a virus-like particle (VLP) vaccine candidate against the H1N1 pandemic influenza virus under ... diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology.